BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33225872)

  • 1. Characterizing Trends in Synthetic Cannabinoid Receptor Agonist Use from Patient Clinical Evaluations during Medical Toxicology Consultation.
    Tebo C; Mazer-Amirshahi M; Wax P; Campleman S; Boyer E; Brent J; Sheth A; Daniuaityte R; Carlson R
    J Psychoactive Drugs; 2021; 53(3):207-214. PubMed ID: 33225872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suspected synthetic cannabinoid receptor agonist intoxication: Does analysis of samples reflect the presence of suspected agents?
    Tebo C; Mazer-Amirshahi M; DeGeorge L; Gelfand B; Leak C; Tolliver S; Sauter D
    Am J Emerg Med; 2019 Oct; 37(10):1846-1849. PubMed ID: 30595429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does cannabis testing in the military drive synthetic cannabinoid use? Self-reported use motivations among justice-involved veterans.
    Santangelo O; Baldwin JM; Stogner J
    Int J Drug Policy; 2022 Aug; 106():103756. PubMed ID: 35738030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis.
    Craft S; Ferris JA; Barratt MJ; Maier LJ; Lynskey MT; Winstock AR; Freeman TP
    Psychopharmacology (Berl); 2022 May; 239(5):1349-1357. PubMed ID: 34533608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intoxications with synthetic cannabinoids].
    Zanen JG; Leegwater E; Schippers EF; Wilms EB
    Ned Tijdschr Geneeskd; 2023 Mar; 167():. PubMed ID: 36943159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Intoxications with synthetic cannabinoids].
    Zanen JG; Leegwater E; Schippers EF; Wilms EB
    Ned Tijdschr Geneeskd; 2023 Feb; 166():. PubMed ID: 36752668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins.
    Banister SD; Connor M
    Handb Exp Pharmacol; 2018; 252():165-190. PubMed ID: 29980914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
    Jackson MA; Brown AL; Johnston J; Clancy R; McGregor I; Bruno R; Lintzeris N; Montebello M; Luksza J; Bowman J; Phung N; Allsop D; Dunlop AJ
    J Cannabis Res; 2021 Jul; 3(1):33. PubMed ID: 34311790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Spice"-related deaths in and around Munich, Germany: A retrospective look at the role of synthetic cannabinoid receptor agonists in our post-mortem cases over a seven-year period (2014-2020).
    Groth O; Roider G; Angerer V; Schäper J; Graw M; Musshoff F; Auwärter V
    Int J Legal Med; 2023 Jul; 137(4):1059-1069. PubMed ID: 37072496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity-based detection of synthetic cannabinoid receptor agonists in plant materials.
    Timmerman A; Balcaen M; Coopman V; Degreef M; Pottie E; Stove CP
    Harm Reduct J; 2024 Jul; 21(1):127. PubMed ID: 38951904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects of cannabis compared to synthetic cannabinoid receptor agonists (SCRAs): a retrospective cohort study of presentations with acute toxicity to European hospitals between 2013 and 2020.
    Waters ML; Dargan PI; Yates C; Dines AM; Eyer F; Giraudon I; Heyerdahl F; Hovda KE; Liechti ME; Miró Ò; Vallersnes OM; Anseeuw K; Badaras R; Bitel M; Bonnici J; Brvar M; Caganova B; Calýskan F; Ceschi A; Chamoun K; Daveloose L; Galicia M; Gartner B; Gorozia K; Grenc D; Gresnigt FMJ; Hondebrink L; Jürgens G; Konstari J; Kutubidze S; Laubner G; Liakoni E; Liguts V; Lyphout C; McKenna R; Mégarbane B; Moughty A; Nitescu GV; Noseda R; O'Connor N; Paasma R; Ortega Perez J; Perminas M; Persett PS; Põld K; Puchon E; Puiguriguer J; Radenkova-Saeva J; Rulisek J; Samer C; Schmid Y; Scholz I; Stašinskis R; Surkus J; Van den Hengel-Koot I; Vigorita F; Vogt S; Waldman W; Waring WS; Zacharov S; Zellner T; Wood DM
    Clin Toxicol (Phila); 2024 Jun; ():1-7. PubMed ID: 38934347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic Cannabinoid-Related Deaths in England, 2012-2019.
    Yoganathan P; Claridge H; Chester L; Englund A; Kalk NJ; Copeland CS
    Cannabis Cannabinoid Res; 2022 Aug; 7(4):516-525. PubMed ID: 33998886
    [No Abstract]   [Full Text] [Related]  

  • 13. Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 UK Psychoactive Substances Act.
    Craft S; Dunn M; Vidler D; Officer J; Blagbrough IS; Pudney CR; Henderson G; Abouzeid A; Dargan PI; Eddleston M; Cooper J; Hill SL; Roper C; Freeman TP; Thomas SHL
    Addiction; 2022 Nov; 117(11):2899-2906. PubMed ID: 35665553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Effects of Synthetic Cannabinoid Receptor Agonists Compared with Marijuana in Emergency Department Patients with Acute Drug Overdose.
    Zaurova M; Hoffman RS; Vlahov D; Manini AF
    J Med Toxicol; 2016 Dec; 12(4):335-340. PubMed ID: 27255136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
    Chung EY; Cha HJ; Min HK; Yun J
    Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic cannabinoid receptor agonists-induced recurrent seizure in elderly patient.
    Andreias L; Roffe E; Eng A; Yiu K; Pashmforoosh G; Khan Z; Rahman R; Kalantari H; Hassen GW
    Am J Emerg Med; 2020 Apr; 38(4):850.e5-850.e6. PubMed ID: 31839517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights.
    Malaca S; Busardò FP; Nittari G; Sirignano A; Ricci G
    Curr Pharm Des; 2022; 28(32):2603-2617. PubMed ID: 34781870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological insights emerging from the characterization of a large collection of synthetic cannabinoid receptor agonists designer drugs.
    Gioé-Gallo C; Ortigueira S; Brea J; Raïch I; Azuaje J; Paleo MR; Majellaro M; Loza MI; Salas CO; García-Mera X; Navarro G; Sotelo E
    Biomed Pharmacother; 2023 Aug; 164():114934. PubMed ID: 37236027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.